ESElse Charlotte Sandset

Else Charlotte Sandset

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Else Charlotte Sandset has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis

    by Mukul Sharma, Lizhen Xu, John W. Eikelboom, Alexander T. Cohen, Andrew M. Demchuk, Anna Członkowska, Arne G. Lindgren, Carlos A. Molina, Daniel Bereczki, Danilo Toni, et al.

    BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0–12.0) and 14.0 days (interquartile range, 10.0–20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33–5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33–4.48]), female sex (HR, 1.78 [95% CI, 1.00–3.16]), and age (HR per year, 1.04 [95% CI, 1.00–1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64–4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76–3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20–3.01]), and age (HR per year, 1.06 [95% CI, 1.03–1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02329327.

  • Clinical Outcome Differences in Asia Versus Non-Asia Intracerebral Hemorrhage: IPD Analysis From BP-Lowering Clinical Trials

    by Shoujiang You, Menglu Ouyang, Tom J. Moullaali, Else Charlotte Sandset, Lisa J. Woodhouse, Qiang Li, Lili Song, Zhe Kang Law, Xinwen Ren, Qiao Han, et al.

    BACKGROUND: Evidence of regional differences in clinical outcomes after intracerebral hemorrhage (ICH) is still scarce. We quantified differential outcomes and response to early intensive blood pressure lowering treatment by region in the Blood pressure in Acute Stroke Collaboration ICH data set. METHODS: This was an observational analysis of pooled individual participant data from 16 completed randomized controlled trials of blood pressure-lowering treatment in acute ICH, based on the Blood pressure in Acute Stroke Collaboration data set. Generalized linear mixed models with inverse probability of treatment weighting (IPTW) were used to determine the association between regions (Asia [primarily East and South Asia] versus non-Asia) and clinical outcomes including neurological deterioration within 7 days, hematoma expansion at 24 hours (absolute ≥6 mL or relative ≥33%), and death or dependency (modified Rankin Scale scores, 3–6), major disability(modified Rankin Scale score, 3–5), death alone at 90 days. RESULTS: Among 6221 patients (age, 63.3±13.0 years; female 36.4%), 3494 (56.2%) were from Asia. ICH participants from Asia had a significantly reduced risk of death or dependency (unadjusted odds ratio [OR], 0.44 [95% CI, 0.39–0.51]; IPTW-weighted OR, 0.67 [95% CI, 0.58–0.77]); and major disability (unadjusted OR, 0.49 [95% CI, 0.42–0.56]; IPTW-weighted OR, 0.67 [95% CI, 0.57–0.78]) at 90 days, neurological deterioration (unadjusted OR, 0.63 [95% CI, 0.52–0.77]; IPTW-weighted OR, 0.70 [95% CI, 0.56–0.89]) within 7 days, in comparison to those from non-Asia regions. However, there were no differences for hematoma expansion ( P =0.97) at 24 hours or death ( P =0.23) at 90 days using IPTW. Additionally, there were no significant interactions between blood pressure–lowering treatment and region (Asia versus non-Asia) for either outcome using IPTW. CONCLUSIONS: Participants from East and South Asia had a favorable functional recovery and a lower risk of neurological deterioration compared with those from non-Asian regions after adjustment for confounders, with no differences in hematoma expansion at 24 hours after ICH. These findings suggest that future ICH studies on clinical outcomes should consider regional differences.

  • Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial

    by John W. Eikelboom, Lizhen Xu, Ashkan Shoamanesh, Qiang Dong, Teruyuki Hirano, Jeffrey L. Saver, Jaime Masjuan, Andrew M. Demchuk, Charlotte Cordonnier, Daniel Bereczki, et al.

    BACKGROUND: OCEANIC-STROKE (XXX) showed that asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing bleeding in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack. We characterized bleeding categories, sites, and key subgroups. METHODS: In the safety population, 12 254 participants received at least 1 dose of asundexian (n=6124) or placebo (n=6130). Bleeding was categorized by International Society on Thrombosis and Haemostasis criteria as major, clinically relevant nonmajor (CRNM), or minor. While-on-treatment analyses included events through 2 days after the last dose, with death and permanent discontinuation as competing risks. RESULTS: Major bleeding occurred in 117 (1.9%) participants with asundexian and 107 (1.7%) with placebo (cause-specific hazard ratio [csHR], 1.10 [95% CI, 0.85–1.44]; P =0.46). Major or CRNM bleeding occurred in 339 (5.5%) and 307 (5.0%), respectively (csHR, 1.12 [95% CI, 0.96–1.30]; P =0.16), and any bleeding in 763 (12.5%) and 752 (12.3%) (csHR, 1.02 [95% CI, 0.93–1.13]; P =0.65). Treatment effects for major and major or CRNM bleeding were consistent across prespecified subgroups, including planned dual antiplatelet therapy. Symptomatic intracranial hemorrhage occurred in 41 (0.7%) and 36 (0.6%) participants. Any gastrointestinal bleeding occurred in 186 (3.0%) and 147 (2.4%) (csHR, 1.28 [95% CI, 1.03–1.59]), and lower gastrointestinal bleeding in 102 (1.7%) and 59 (1.0%) (csHR, 1.75 [95% CI, 1.27–2.41]), primarily rectal bleeding. Any procedure-related bleeding and any mucosal bleeding did not differ significantly. CONCLUSIONS: Asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing major, major or CRNM, or any bleeding. Lower gastrointestinal bleeding was more frequent with asundexian, whereas treatment effects on major and major or CRNM bleeding were consistent across prespecified subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05686070.

  • Open Access

    Incidence, clinical characteristics and outcome of spontaneous cerebellar intracerebral haemorrhage in a Norwegian population.

    by Silje Holt Jahr, Nojoud Koubaa, Vigdis Hillestad, Kristin Tveitan Larsen, Maiken Nordahl Selseth, Trine Lied-Herland, Jarle Sundseth, Else Charlotte Sandset, Ole Morten Rønning, Espen Saxhaug Kristoffersen

    Cerebellar ICH accounts for 5%-10% of spontaneous ICH, yet cerebellar-specific incidence data are sparse and the unselected clinical spectrum and outcomes remain poorly characterised. We retrospectively identified all adults (≥18 years) in the catchment area of a Norwegian stroke centre with spontaneous cerebellar ICH between 2009 and 2024, using discharge codes and radiological verification. We calculated crude and age-standardised incidence rates with 95% CIs, and assessed clinical characteristics, functional outcome (mRS) and mortality to 1 year. Among 129 admissions (median age 75 years; 47% women), 120 were incident cases. Age-standardised incidence was 2.6 per 100,000 person-years (95% CI, 2.1-3.0), rising from 0.3 at < 55 to 21.0 at ≥ 85 years, and remained stable over 16 years (incidence rate ratio 0.97/year; 0.93-1.00). Median haematoma volume was 8.1 mL (mean 11.2 mL); one-third were anticoagulated; 13% underwent neurosurgery. Care limitation was frequent (45%; 64% aged ≥ 75). In-hospital mortality was 31% and 1-year mortality 41%; median time to death was 3 days. At 3 months, 29% achieved functional independence (mRS 0-2), and 36% when restricted to early-phase survivors (>3 days). Compared with tertiary surgical series, this unselected cohort had smaller haematomas and a lower surgical rate. Frequent care limitation in older patients reflects clinical reality outside referral centres. Cerebellar ICH is rare, with an age gradient mirroring that of ICH overall. Although prognosis is dominated by early deaths, 1 in 3 acute-phase survivors regain functional independence, indicating that outcome is not uniformly poor. ClinicalTrials.gov, NCT05378490.

  • Open Access

    Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial

    by Ashkan Shoamanesh, Stuart J. Connolly, Andrew M. Demchuk, David J. Seiffge, Else Charlotte Sandset, Carlos A. Molina, Georgios Tsivgoulis, Hanne Christensen, Jan Beyer-Westendorf, Jonathan M. Coutinho, et al.

    BACKGROUND: Andexanet improves hemostatic efficacy in FXa (factor Xa) inhibitor–associated intracranial hemorrhage but carries a risk of thrombotic events. These secondary analyses of the ANNEXA-I trial (A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor) examined determinants of hematoma expansion (HE) and the corresponding response to andexanet. METHODS: ANNEXA-I enrolled patients aged ≥18 years with acute FXa inhibitor–associated intracranial hemorrhage within 6 hours of onset between June 6, 2019, and May 27, 2023, at 131 sites in 23 countries. Participants were randomized (1:1) to andexanet or usual care. Among 530 participants, 459 (87%) had a qualifying intracerebral hemorrhage and adequate brain imaging for these analyses. The primary outcome was HE (≥12.5-mL or ≥35% increase in baseline volume) at 12 hours. We report differences in the proportion of HE between treatment groups stratified by variables significantly associated with HE in regression models. RESULTS: HE occurred in 149 of 459 participants (32.5%). Symptom onset-to-treatment time (adjusted odds ratio per hour, 0.73 [95% CI, 0.63–0.85]), baseline hematoma volume (adjusted odds ratio per 10 mL, 1.11 [95% CI, 1.01–1.23]), and diastolic blood pressure (adjusted odds ratio per 10 mm Hg, 1.15 [95% CI, 1.02–1.29]) were associated with HE but not thrombotic events. In a separate multivariable model replacing volume and onset-to-treatment time with prescan hematoma growth rate, growth rate was also associated with HE (adjusted odds ratio per mL/h, 1.02 [95% CI, 1.01–1.04]). Patients in the highest risk quartiles (baseline volume >22.4 mL, growth rate >11.4 mL/h, diastolic blood pressure >95.0 mm Hg, and onset-to-treatment time ≤3.3 hours) had ≈50% to 60% absolute risk of HE with usual care. Numerically greater absolute risk reductions with andexanet (≈25%; number needed to treat: 4) were observed in the highest quartiles of baseline volume and growth rate. CONCLUSIONS: Shorter onset-to-treatment time, larger baseline hematoma volume, higher diastolic blood pressure, and higher prescan hematoma growth rate predict HE but not thrombotic events in FXa inhibitor–associated intracerebral hemorrhage. Andexanet benefit is observed across these ranges and may be amplified through patient selection using these metrics. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03661528.


  • Study of Antithrombotic Treatment After Intracerebral Hemorrhage-Antiplatelets: A Randomized Trial

    by Helle Eilertsen, Kristin Tveitan Larsen, Elisabeth Forfang, Johanna Pennlert, Eva-Lotta Glader, Christina Kruuse, Per Wester, Hege Ihle-Hansen, Maria Carlsson, Trine Lied-Herland, et al.

    BACKGROUND: Patients surviving spontaneous intracerebral hemorrhage (ICH) who have indications for antithrombotic treatment face increased risks of both hemorrhagic and ischemic events. The aim of STATICH (Study of Antithrombotic Treatment After Intracerebral Haemorrhage) was to assess the safety and efficacy of long-term antithrombotic treatment after ICH. METHODS: STATICH Antiplatelets (EudraCT 2014-002636-13; Unique identifier: NCT03186729) was a randomized, multicenter, open, blinded end point parallel-group trial, including adults with an indication for antiplatelet treatment to either start or avoid antiplatelet treatment. The target sample size was 500 participants. Patients were allocated 1:1 by a Web-based randomization system and followed for a minimum of 2 years. Outcome assessments were done by personnel blinded to treatment. Participants were not blinded. The primary safety outcome was recurrent symptomatic ICH. RESULTS: The trial was stopped early due to slow recruitment. Sixty-nine patients were included between August 2018 and December 2022: 34 were randomized to start antiplatelet treatment, and 35 were randomized to avoid antiplatelet treatment. No patients were excluded from analyses. The median age was 75 (Q1–Q3, 66–80) years, and 43 (75%) had previous ischemic stroke or transient ischemic attack. Five patients in the start antiplatelet treatment group (15% [95% CI, 6%–31%]), and 1 in the avoid group (3% [95% CI, 0%–18%]) experienced recurrent ICH, while 3 (9% [95% CI, 3%–24%]) and 7 (20% [95% CI, 10%–37%]), respectively, experienced a major ischemic event. A total of 88 serious adverse events and no suspected unexpected serious adverse reactions were registered. CONCLUSIONS: There were numerically more recurrent ICHs and fewer ischemic events in patients starting antiplatelet treatment after ICH compared with those avoiding antiplatelet treatment. The slow recruitment might be due to clinicians being certain of the best treatment strategy or patients being too frail to participate. STATICH will contribute to a planned collaborative individual patient-data meta-analysis to resolve this dilemma.

  • Open Access

    Diagnostic performance of prehospital large-vessel occlusion detection scales in patients with suspected acute stroke: a retrospective validation study. The Akershus Study of Ischemic Stroke and Thrombolysis

    by Silje Holt Jahr, Maiken Nordahl Selseth, Kristin Tveitan Larsen, Antje Sabine Reichenbach, Marianne Altmann, Antje Sundseth, Vigdis Hillestad, Helge Fagerheim Bugge, Anne-Cathrine Braarud, Maren Ranhoff Hov, et al.

    Introduction: Prehospital stroke scales are widely used to identify patients with suspected stroke. The scales have shown potential to identify suspected large-vessel occlusion (LVO) for direct-to-thrombectomy triage, yet it remains unclear which scales perform best, and whether performance varies by patient characteristics. Patients and methods: In this retrospective diagnostic accuracy study, we analysed 1150 consecutive adults admitted under the stroke code protocol at a primary stroke centre (January 2015–December 2017). The cohort included ischaemic stroke, transient ischaemic attack, intracerebral haemorrhage and mimics. We evaluated 55 scale–threshold combinations (46 scales) for detection of computed tomography angiography (CTA)–confirmed LVO, quantified by area under the receiver operating characteristic curve (AUC), sensitivity, specificity and predictive values. Results: In our study population, LVO prevalence was 13.5%. AUC ranged from 0.586 (Hemiplegia) to 0.855 (FAST-ED). No scale significantly outperformed the continuous National Institutes of Health Stroke Scale (NIHSS, AUC 0.851) after Bonferroni correction, and none achieved both sensitivity and specificity above 80%. Scales combining cortical and motor items outperformed purely motor-based instruments. Accuracy was comparable between sexes but higher for left-hemispheric strokes (mean AUC: 0.82 vs 0.76) and patients aged ≥60 years (0.82 vs 0.77). Discussion: None of the prehospital stroke scales were accurate enough to reliably detect LVO. Performance varied with stroke laterality, patient age and stroke severity—approaching chance levels at the extremes of severity and showing a consistent hemispheric bias. Conclusion: This highlights fundamental limitations of using clinical scales alone to detect LVO in real-world stroke code populations. Registration: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05378490, NCT05378490.

  • Top Cited Papers
    Open Access

    2025 update to European Stroke Organisation (ESO) guideline on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage

    by Else Charlotte Sandset, Lina Palaiodimou, Silje Holt Jahr, Leonard Ho, Urs Fischer, Aristeidis H Katsanos, Kailash Krishnan, Benjamin Maïer, Eva A Mistry, Simona Sacco, et al.

    Optimal blood pressure (BP) management in acute ischaemic stroke (AIS) and acute ICH remains uncertain. In light of new data published since the previous ESO guidelines, this update provides revised, evidence-based recommendations across 8 key clinical questions to support BP management in acute stroke. The guidelines were developed using the ESO standard operating procedure and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology, including literature searches, systematic reviews and meta-analyses of relevant RCTs, assessment of evidence quality and formulation of specific recommendations. We advise against routine pre-hospital BP lowering in suspected stroke (moderate-certainty evidence). In AIS patients undergoing reperfusion therapy, we recommend maintaining BP < 185/110 mmHg before the bolus of intravenous thrombolysis and < 180/105 mmHg during and for 24 h after intravenous thrombolysis (low-certainty evidence) and/or mechanical thrombectomy (moderate-certainty evidence). We recommend against intensively lowering systolic BP < 140 mmHg in the first 24 h after successful mechanical thrombectomy (high-certainty evidence). Routine use of vasopressors to raise BP in AIS patients with neurological deterioration who are not treated with acute reperfusion therapies is discouraged (low-certainty evidence). In acute ICH, the net clinical benefit of intensive BP lowering remains uncertain; however, expert consensus supports early systolic BP reduction to < 140 mmHg in patients with small-to-moderate haematomas to limit haematoma expansion. Overall, the updated recommendations reaffirm the core principles of current clinical practice while providing more nuanced guidance for specific scenarios. However, the quality of evidence remains moderate to very low, limited by a lack of high-quality RCTs, methodological issues, inconsistent results and study heterogeneity. Consequently, most recommendations are weak and supported by expert consensus. These guidelines provide specific recommendations on BP thresholds and management strategies tailored to distinct acute stroke subgroups. They also highlight the ongoing uncertainty and emphasise the need for future RCTs to define optimal BP targets, timing, treatment strategies and ideal antihypertensive agents across different clinical contexts.


  • Open Access

    Presenting symptoms and diagnostic accuracy of prehospital stroke scales for patients with suspected mild minor stroke

    by Helge Fagerheim Bugge, Mona Guterud, Karianne Larsen, Mathias Toft, Maren Ranhoff Hov, Else Charlotte Sandset

    Introduction: Identifying patients with minor stroke is challenging in the prehospital setting due to subtle symptoms. The majority of studies evaluating prehospital stroke scales include patients with high median NIHSS at admission. ParaNASPP, a stepped-wedge cluster-randomized controlled trial found that prehospital NIHSS identified more patients with minor symptoms. Further knowledge on presenting symptoms of patients with suspected minor stroke, and the accuracy of prehospital stroke scales on minor stroke is needed. Methods: A post-hoc analysis of data from the ParaNASPP trial describes prehospital presenting signs and symptoms of patients with suspected mild minor stroke. We defined mild minor stroke as NIHSS 0–2 at hospital admission. Furthermore, we reconstructed and evaluated nine prehospital stroke scales (NIHSS, FAST/CPSS, BE-FAST, LAPSS, MASS, MedPacs, PreHAST, and sNIHSS-EMS) in patients with mild minor stroke. Results: Four hundred and thirty-one patients in the ParaNASPP trial had NIHSS 0–2 at hospital admission. Of these, 152 (35%) were discharged from hospital with a stroke diagnosis. When examined by paramedics, stroke patients presented with speech disturbance, facial palsy, and motor weakness in arm or leg, while stroke mimics presented with dizziness, headache, and nausea/vomiting. NIHSS had the highest sensitivity (95%) and lowest specificity (16%), while LAPSS had the lowest sensitivity (42%) and highest specificity (80%) in the patients with suspected mild minor stroke. The remaining scales had sensitivity between 67% and 93%, and specificity between 23% and 67%. Conclusions: In patients with mild minor stroke, substantial overlap in presentation between stroke and stroke mimics makes triage challenging. Prehospital stroke scales provide either high sensitivity or specificity. Competence and training of paramedics in when and how to use, and interpret, these scales is key for recognizing and correctly triaging stroke patients. The ParaNASPP trial was registered at Clinicaltrials.gov with registration number NCT04137874.


  • Addressing sex and gender differences in stroke risk and management: A scientific statement from the World Stroke Organization

    by Cheryl Carcel, Else Charlotte Sandset, Mariam Ali, Maria Ignacia Allende Echanez, Maria Giulia Mosconi, Ana Cláudia de Souza, Lachlan L Dalli, Paula Munoz Venturelli, Yuki Sakamoto, Ahmed Nasreldein, et al.

    This World Stroke Organization Scientific Statement highlights how sex and gender differences shape stroke risk, treatment, care, and research. Estrogen confers a relative protection before menopause, with risk increasing thereafter. Beyond shared cardiovascular determinants (hypertension, atrial fibrillation, and diabetes), women face sex-specific risks—hypertensive disorders of pregnancy, menopause, and hormone therapy, with clear implications for stroke prevention and management. Despite comparable efficacy of acute and secondary stroke therapies in women and men, women are less likely to receive timely acute treatment and often experience delays in recognition and access. The statement recommends gender-responsive prevention and care pathways; systematic consideration of pregnancy-related and menopausal factors; and public and professional education to improve stroke symptom recognition and purposeful inclusion of women across the research continuum. By integrating evidence from epidemiology, acute care, and secondary prevention, this statement provides clear and timely guidance for reducing inequities and shaping future research and policy to achieve equitable stroke care globally.